指南与共识免疫规划传染病防控与疫情报告

美国ACIP关于≥16岁人群使用辉瑞-BioNTech COVID-19疫苗的推荐(2021年9月)

Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2021-09-24

美国ACIP基于证据到推荐框架和GRADE方法,于2021年8月30日推荐≥16岁人群使用辉瑞-BioNTech COVID-19疫苗预防COVID-19。该推荐基于临床试验随访、真实世界疫苗有效性研究和上市后安全性监测,认为预防无症状感染、COVID-19及相关住院和死亡的获益超过疫苗相关风险。

要点

  • ACIP推荐≥16岁人群使用辉瑞-BioNTech COVID-19疫苗预防COVID-19。
  • 推荐基于EtR框架和GRADE方法,证据确定性因额外信息而提高。
  • 疫苗基础免疫为2剂30 μg肌内注射,间隔3周。

核心结论

  • ACIP推荐≥16岁人群使用辉瑞-BioNTech COVID-19疫苗预防COVID-19。

研究设计与样本

  • ACIP于2021年8月30日公开会议发布推荐,采用EtR框架和GRADE方法评估证据。

主要发现

  • 额外临床试验随访、真实世界疫苗有效性研究和上市后安全性监测增加了获益超过风险的确定性。

关键数值与推荐

  • 推荐≥16岁人群使用辉瑞-BioNTech COVID-19疫苗。
  • 疫苗基础免疫为2剂30 μg(0.3 mL)肌内注射,间隔3周。

临床怎么用

  • 对≥16岁人群按2剂30 μg、间隔3周接种辉瑞-BioNTech COVID-19疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) is a lipid nanoparticle-formulated, nucleoside mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. In December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) as well as an interim recommendation for use among persons aged ≥16 years by the Advisory Committee on Immunization Practices (ACIP) (1). In May 2021, the EUA and interim ACIP recommendations for Pfizer-BioNTech COVID-19 vaccine were extended to adolescents aged 12-15 years (2). During December 14, 2020-September 1, 2021, approximately 211 million doses of Pfizer-BioNTech COVID-19 vaccine were administered in the United States.* On August 23, 2021, FDA approved a Biologics License Application for use of the Pfizer-BioNTech COVID-19 vaccine, Comirnaty (Pfizer, Inc.), in persons aged ≥16 years (3). The ACIP COVID-19 Vaccines Work Group's conclusions regarding the evidence for the Pfizer-BioNTech COVID-19 vaccine were presented to ACIP at a public meeting on August 30, 2021. To guide its deliberations regarding the Pfizer-BioNTech COVID-19 vaccine, ACIP used the Evidence to Recommendation (EtR) Framework,† and incorporated a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.§ In addition to initial clinical trial data, ACIP considered new information gathered in the 8 months since issuance of the interim recommendation for Pfizer-BioNTech COVID-19 vaccine, including additional follow-up time in the clinical trial, real-world vaccine effectiveness studies, and postauthorization vaccine safety monitoring. The additional information increased certainty that benefits from prevention of asymptomatic infection, COVID-19, and associated hospitalization and death outweighs vaccine-associated risks. On August 30, 2021, ACIP issued a recommendation¶ for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Dooling K, Gargano JW, Moulia D, et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34555007. doi:10.15585/mmwr.mm7038e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。